LivaNova PLC (LIVN) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems.
Is LivaNova PLC stock overvalued or undervalued in 2026?
LivaNova PLC (LIVN) trades at 23.7× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $103 (+28 %).
Kaplio overview: LivaNova PLC
Market cap $4B · 52 weeks $50 – $85 (5 % below the high) · P/E 23.7× · 2027 expected P/E 17.2× · Dividend none · Next earnings November 4, 2026 · expected EPS $1.06 · Closing price, Oct 29 · accounts published Aug 5.
- Valuation: P/E 23.7× (cheap).
- Business: ROIC 10 % (fair).
- Balance sheet: Net debt/EBITDA 1.3× (solid).
- Earnings: 8 of 8 (uneven).
What would it be worth at its usual multiples?
At its sector median (30.4×) $103 (+28 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 1 of 4 pass
- R&D / Revenue 13.4 %, fails.
- ROIC 10.2 %, fails.
- Gross margin 67.7 %, borderline.
- Net debt / EBITDA 1.3×, passes.
Against its peers (reference peers) — LivaNova PLC: P/E 23.7×; EV/EBITDA 19.9×; ROIC 10.2 %; $4.4B. Haemonetics Corporation (P/E 58.7×; EV/EBITDA 24.5×; ROIC 8.6 %; $5.5B), Inspire Medical Systems, Inc. (P/E 15.4×; EV/EBITDA 23.6×; ROIC 6.3 %; $2.1B), Edwards Lifesciences Corporation (P/E 54.3×; EV/EBITDA 32.0×; ROIC 10.2 %; $54.4B).
Profitability
| Return on Equity | 15.41% |
| Return on Invested Capital | 10.19% |
| Return on Assets | 7.14% |
| Gross Margin | 68.18% |
| Operating Margin | 13.48% |
| Net Margin | 12.82% |
Financial Health
| Debt / Equity | 0.27 |
| Current Ratio | 1.45 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 2.35 |
Price Performance
| 1 month | +6.21% |
| 3 months | +1.39% |
| Year-to-date | +32.05% |
| 1 year | +53.91% |
| 3 years | +65.65% |
| 5 years | +5.90% |
| 10 years | +44.39% |
Related companies: BSX · MDT · EW · RMD · HAE · INSP
Explore sector: Healthcare · Medical - Devices
More sections of LIVN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks